BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32768508)

  • 1. First experience with model-based selection of head and neck cancer patients for proton therapy.
    Tambas M; Steenbakkers RJHM; van der Laan HP; Wolters AM; Kierkels RGJ; Scandurra D; Korevaar EW; Oldehinkel E; van Zon-Meijer TWH; Both S; van den Hoek JGM; Langendijk JA
    Radiother Oncol; 2020 Oct; 151():206-213. PubMed ID: 32768508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTV-based VMAT vs. robust IMPT for head-and-neck cancer: A probabilistic uncertainty analysis of clinical plan evaluation with the Dutch model-based selection.
    Rojo-Santiago J; Korevaar E; Perkó Z; Both S; Habraken SJM; Hoogeman MS
    Radiother Oncol; 2023 Sep; 186():109729. PubMed ID: 37301261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of advanced preselection tools to reduce redundant plan comparisons in model-based selection of head and neck cancer patients for proton therapy.
    Tambas M; van der Laan HP; Rutgers W; van den Hoek JGM; Oldehinkel E; Meijer TWH; van der Schaaf A; Scandurra D; Free J; Both S; Steenbakkers RJHM; Langendijk JA
    Radiother Oncol; 2021 Jul; 160():61-68. PubMed ID: 33892024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients.
    de Jong BA; Battinelli C; Free J; Wagenaar D; Engwall E; Janssens G; Langendijk JA; Korevaar EW; Both S
    Med Phys; 2023 Mar; 50(3):1305-1317. PubMed ID: 36373893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
    Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
    Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model based clinic.
    de Jong BA; Korevaar EW; Maring A; Werkman CI; Scandurra D; Janssens G; Both S; Langendijk JA
    Radiother Oncol; 2023 Jul; 184():109670. PubMed ID: 37059337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction.
    Scorsetti M; Cozzi L; Navarria P; Fogliata A; Rossi A; Franceschini D; De Rose F; Franzese C; Carlo-Stella C; Santoro A
    Radiat Oncol; 2020 Jan; 15(1):12. PubMed ID: 31931861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35.
    Hansen CR; Jensen K; Smulders B; Holm AIS; Samsøe E; Nielsen MS; Sibolt P; Skyt P; Elstrøm UV; Nielsen CP; Johansen J; Zukauskaite R; Eriksen JG; Farhadi M; Andersen M; Andersen E; Overgaard J; Grau C; Friborg J
    Radiother Oncol; 2024 Jan; 190():109812. PubMed ID: 37479061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment planning comparison for head and neck cancer between photon, proton, and combined proton-photon therapy - From a fixed beam line to an arc.
    Amstutz F; Krcek R; Bachtiary B; Weber DC; Lomax AJ; Unkelbach J; Zhang Y
    Radiother Oncol; 2024 Jan; 190():109973. PubMed ID: 37913953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effect of setup uncertainty reduction and adaptation to geometric changes on normal tissue complication probability using online adaptive head and neck intensity modulated proton therapy.
    Lalonde A; Bobić M; Sharp GC; Chamseddine I; Winey B; Paganetti H
    Phys Med Biol; 2023 May; 68(11):. PubMed ID: 37164020
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of organ-at-risk sparing and plan robustness for spot-scanning proton therapy and volumetric modulated arc photon therapy in head-and-neck cancer.
    Barten DL; Tol JP; Dahele M; Slotman BJ; Verbakel WF
    Med Phys; 2015 Nov; 42(11):6589-98. PubMed ID: 26520750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of setup and range uncertainties on TCP and NTCP following VMAT or IMPT of oropharyngeal cancer patients.
    Hamming-Vrieze O; Depauw N; Craft DL; Chan AW; Rasch CRN; Verheij M; Sonke JJ; Kooy HM
    Phys Med Biol; 2019 Apr; 64(9):095001. PubMed ID: 30921775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robustness assessment of clinical adaptive proton and photon radiotherapy for oesophageal cancer in the model-based approach.
    Visser S; O Ribeiro C; Dieters M; Mul VE; Niezink AGH; van der Schaaf A; Knopf AC; Langendijk JA; Korevaar EW; Both S; Muijs CT
    Radiother Oncol; 2022 Dec; 177():197-204. PubMed ID: 36368472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
    Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMPT of head and neck cancer: unsupervised machine learning treatment planning strategy for reducing radiation dermatitis.
    Padannayil NM; Sharma DS; Nangia S; Patro KC; Gaikwad U; Burela N
    Radiat Oncol; 2023 Jan; 18(1):11. PubMed ID: 36639667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust Intensity Modulated Proton Therapy (IMPT) Increases Estimated Clinical Benefit in Head and Neck Cancer Patients.
    van Dijk LV; Steenbakkers RJ; ten Haken B; van der Laan HP; van 't Veld AA; Langendijk JA; Korevaar EW
    PLoS One; 2016; 11(3):e0152477. PubMed ID: 27030987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton vs photon: A model-based approach to patient selection for reduction of cardiac toxicity in locally advanced lung cancer.
    Teoh S; Fiorini F; George B; Vallis KA; Van den Heuvel F
    Radiother Oncol; 2020 Nov; 152():151-162. PubMed ID: 31431365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head.
    Raturi VP; Hojo H; Hotta K; Baba H; Takahashi R; Rachi T; Nakamura N; Zenda S; Motegi A; Tachibana H; Ariji T; Motegi K; Nakamura M; Okumura M; Hirano Y; Akimoto T
    Radiat Oncol; 2020 Jun; 15(1):157. PubMed ID: 32571379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partitioning of discrete proton arcs into interlaced subplans can bring proton arc advances to existing proton facilities.
    Engwall E; Marthin O; Wase V; Sundström J; Mikhalev V; de Jong BA; Langendijk JA; Melbéus H; Andersson B; Korevaar EW; Both S; Bokrantz R; Glimelius L; Fredriksson A
    Med Phys; 2023 Sep; 50(9):5723-5733. PubMed ID: 37482909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An comparison of acute toxicities and patient-reported outcomes between intensity-modulated proton therapy and volumetric-modulated arc therapy after ipsilateral radiation for head and neck cancers.
    Jeans EB; Shiraishi S; Manzar G; Morris LK; Amundson A; McGee LA; Rwigema JC; Neben-Wittich M; Routman DM; Ma DJ; Patel SH; Foote RL; Lester SC
    Head Neck; 2022 Feb; 44(2):359-371. PubMed ID: 34859516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.